Ignite Creation Date:
2025-12-24 @ 7:57 PM
Ignite Modification Date:
2026-03-03 @ 6:46 PM
Study NCT ID:
NCT01920204
Status:
UNKNOWN
Last Update Posted:
2015-01-19
First Post:
2013-08-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Midostaurin in Indolent Systemic Mastocytosis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D034721', 'term': 'Mastocytosis, Systemic'}, {'id': 'D008415', 'term': 'Mastocytosis'}], 'ancestors': [{'id': 'D009372', 'term': 'Neoplasms, Connective Tissue'}, {'id': 'D018204', 'term': 'Neoplasms, Connective and Soft Tissue'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D000090362', 'term': 'Mast Cell Activation Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C059539', 'term': 'midostaurin'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 20}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2013-08'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2015-01', 'completionDateStruct': {'date': '2015-05', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2015-01-15', 'studyFirstSubmitDate': '2013-08-07', 'studyFirstSubmitQcDate': '2013-08-07', 'lastUpdatePostDateStruct': {'date': '2015-01-19', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2013-08-09', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-03', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Symptom Scoring', 'timeFrame': '12 weeks', 'description': 'Percent change in the total score ("Sumscore") of all symptoms assessed by the Mastocytosis Symptom Assessment Form (MSAF) after 12 weeks.'}], 'secondaryOutcomes': [{'measure': 'Persistence of improvements', 'timeFrame': '6 months', 'description': 'persistence of improvement symptom score at 6 months.'}, {'measure': 'Mast cell burden', 'timeFrame': '6 months', 'description': 'Percent change in the mast cell burden (bone marrow infiltrate, skin infiltrate, serum tryptase levels) after 6 months.'}, {'measure': 'Adverse events', 'timeFrame': '6 months', 'description': 'Number and grading of Common Terminology Criteria adverse events during the 6 months of therapy.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Mastocytosis', 'ISM', 'SSM'], 'conditions': ['Indolent Systemic Mastocytosis']}, 'referencesModule': {'references': [{'pmid': '29890238', 'type': 'DERIVED', 'citation': 'van Anrooij B, Oude Elberink JNG, Span LFR, de Monchy JGR, Rosati S, Mulder AB, Kluin-Nelemans JC. Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial. J Allergy Clin Immunol. 2018 Sep;142(3):1006-1008.e7. doi: 10.1016/j.jaci.2018.06.003. Epub 2018 Jun 8. No abstract available.'}]}, 'descriptionModule': {'briefSummary': 'Rationale: Patients with indolent or smoldering systemic mastocytosis can have severe disabling symptoms. Almost all patients have fatigue, a compromised quality of life, hampering normal functioning. Because this form of mastocytosis is not considered life-threatening, mast cell eradication has never been applied and patients receive only symptomatic therapy with histamine blockers. Midostaurin, a c-KIT inhibitor has shown activity regarding symptom control and decrease of malignant mast cells in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia', 'detailedDescription': 'Objective:\n\nPrimary: To study in a pilot phase II trial the efficacy of midostaurin administered at an oral dose of 100 mg twice daily in patients with indolent or smoldering systemic mastocytosis on mediator symptom reduction, documented by the Mastocytosis Symptom Assessment Questionnaire, measured at 3 months.\n\nSecondary:\n\n1. To study whether symptom improvement persists at 6 months, and whether midostaurin can reduce mast cell infiltration in the skin and bone marrow, documented by decrease of serum tryptase, decrease of urticaria pigmentosa and decrease of bone marrow mast cells.\n2. To assess safety and tolerability of midostaurin in the above mentioned settings\n\nStudy design: Single arm, open label pilot phase II study.\n\nStudy population: Adult patients (n=20) with histologically documented systemic mastocytosis, indolent or smoldering subtype, with severe symptoms, not controlled by histamine 1 and 2 blockers.\n\nIntervention: treatment with Midostaurin, twice daily 100 mg orally for 6 months continuously.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients with Indolent Systemic Mastocytosis (ISM) or Smouldering Systemic Mastocytosis (SSM) according to the WHO criteria\n* Presence of the D816V c-KIT mutation\n* Serum tryptase \\> 20 mg/l\n* Serious mediator-related symptoms that cannot be controlled by H1 and H2 blocking drugs. Symptoms will be scored by an adapted MSAF (mastocytosis symptom assessment form) with at least:\n\n * a pre-study score of 4 or more on 3 non-related items,\n * or a pre-study score of 5 or more on 2 non-related items.\n * one item from the scoring list can be replaced by flushes 7 or more per week or anaphylactic attacks 1 or more per week.\n* Age \\>18 years\n* Willingness to apply optimal contraceptive measures (double barrier method, both men and women) for women below the age of 55, men at all ages; for both: if sexually active.\n* Written informed consent\n\nExclusion Criteria:\n\n* Aggressive systemic mastocytosis, mast cell leukemia, or ASM with or without accompanying non-clonal related non-mast cell disorder (SM-ANHMD).\n* Any known other present malignancy, non-melanoma skin cancers excluded\n* History of malignancy within the last 5 years, non-melanoma skin cancers excluded\n* Any serious comorbidity interfering with therapy compliance and follow-up compliance\n* Pregnancy\n* Patients not willing or who are not able to comply with contraceptive measures'}, 'identificationModule': {'nctId': 'NCT01920204', 'briefTitle': 'Midostaurin in Indolent Systemic Mastocytosis', 'organization': {'class': 'OTHER', 'fullName': 'University Medical Center Groningen'}, 'officialTitle': 'Phase II Single Arm Open Pilot Study to Demonstrate the Efficacy of Midostaurin in Symptom Improvement and Decrease of Mast Cell Burden in Patients With Indolent or Smoldering Systemic Mastocytosis.', 'orgStudyIdInfo': {'id': 'UMCG41973'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Midostaurin', 'description': 'Treatment with Midostaurin, twice daily 100 mg orally for 6 months continuously.', 'interventionNames': ['Drug: Midostaurin,']}], 'interventions': [{'name': 'Midostaurin,', 'type': 'DRUG', 'otherNames': ['PKC412'], 'description': 'Midostaurin, twice daily 100 mg orally, continuously for 6 months', 'armGroupLabels': ['Midostaurin']}]}, 'contactsLocationsModule': {'locations': [{'zip': '9700RB', 'city': 'Groningen', 'state': 'Provincie Groningen', 'country': 'Netherlands', 'facility': 'University Medical Center Groningen', 'geoPoint': {'lat': 53.21917, 'lon': 6.56667}}], 'overallOfficials': [{'name': 'J.C. Kluin-Nelemans, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University Medical Center Groningen'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University Medical Center Groningen', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Prof.dr.', 'investigatorFullName': 'Prof.dr. J.C. Kluin-Nelemans', 'investigatorAffiliation': 'University Medical Center Groningen'}}}}